Kevin Dalgaard
Principal
Principal at Lundbeckfonden BioCapital.
Kevin joins from Boehringer Ingelheim where he as a Strategic Partner in Business Development has successfully been leading global licensing activities within Cardiometabolism and Retinal Health. Prior to that, Kevin worked at Novo Nordisk for several years in various positions within R&D, Global Marketing, and Business Development providing him a great insight and understanding of the whole value chain in the pharma industry.
Kevin holds an MSc in Biochemistry from the University of Copenhagen, and a Ph.D. from Max Planck Institute. Kevin has several high-impact publications including a first-author publication in ‘Cell’.
Board Observer: Notify Therapeutics, VarmX, Vesper Biotechnology
